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Out of a total of 311Mycobacterium tuberculosis isolates from sputum specimens subjected to
first- and second-line drug-susceptibility testing (DST) at a hospital serving as a referral
center for chronic tuberculosis (TB) cases in New Delhi, 232/311 (74.6%) isolates were found
to be resistant to isoniazid and rifampicin. Among multidrug-resistant (MDR) isolates, 119/
232 (51.3%) were resistant to four first-line drugs (streptomycin, isoniazid, rifampicin and
ethambutol). Mono-resistance to isoniazid was observed in 18 (5.7%) isolates, while none
of the isolates tested showed mono-resistance to rifampicin. 50/232 (21.5%) isolates met
the definition of extensively drug resistant (XDR) TB, i.e., additional resistance to a fluoro-
quinolone and at least one of the three injectable second-line drugs: kanamycin, capreo-
mycin, or amikacin. Spoligotyping of the XDR-TB isolates revealed 14 patterns; 39/50
(78%) isolates being grouped in three clusters vs. 11/50 (22%) isolates being unique. SIT1/
Beijing represented the largest cluster (n = 21, 42%), followed by SIT26/CAS1-Delhi (n = 10,
20%) and SIT 53/T1 (n = 8 isolates; 16%). This study corroborates recent observations from
North India suggesting that both Beijing and CAS1-Delhi lineages constitute the bulk of
XDR-TB isolates that are disseminating rapidly across a large geographical region in and
around the capital city of India.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
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tional resistance to a fluoroquinolone and at least one of
the three injectable second-line drugs: kanamycin, capreomy-
cin, or amikacin [2].
A recently published study showed high levels of MDR-TB
in both new and treatment-failure patients from the Revised
National Tuberculosis Control Program (RNTCP) in four sub-
optimally performing municipal wards of Mumbai [3]. The
authors determined the extent of drug resistance in 724 cases
of pulmonary TB (493 newly diagnosed, and 231 first-line
treatment-failure cases, i.e., sputum-smear positive at the
fifth month after commencement of therapy), and reported
an astoundingly high proportion of MDR-TB strains in both
previously untreated (24%) and treatment-failure cases
(41%). These numbers are much higher than the World Health
Organization (WHO) [4] and the National Reference Labora-
tory for the RNTCP [5] figures that report MDR-TB amongst
new and retreated TB patients in India: around 2.3% (range
1.8–2.8) and 17.2% (range 14.9–19.5), respectively. Hence, the
figures generated through sampling of patients accessing a
tertiary care center, although ‘‘unrepresentative’’ at the na-
tional level, are clearly a cause for concern.
Recent reports have singled out India as having the great-
est burden of XDR-TB in the South Asian subcontinent, with a
poor prognosis and high mortality among HIV-infected indi-
viduals [6–8]. Hence, early detection is essential in arresting
further transmission of XDR-TB clones, which is much more
expensive to manage owing to prolonged medication and
high risk of death. In this grim context, the study of TB epide-
miology through DNA fingerprinting is an important tool con-
tributing to the understanding of transmission and control of
TB. Spoligotyping targeting the DNA polymorphism at the di-
rect repeat locus (DR locus) of the genome of Mycobacterium
tuberculosis complex allows simultaneous detection and dif-
ferentiation of M. tuberculosis complex strains. This polymer-
ase chain reaction (PCR)-based method requiring a small
amount of DNA is a rapid, robust and cost-effective genotyp-
ing technique. Though there have been recent studies charac-
terizing MDR-TB isolates from Delhi [9–11] and they have
reported SIT26 as the predominant spoligotype in northern
India, studies highlighting genotypic diversity among XDR-
TB isolates in India remain rare. Consequently, the present
study was aimed at molecular characterization of the XDR
M. tuberculosis clinical isolates from a tertiary care TB hospital
in order to obtain an initial insight into the predominant spo-
ligotypes and to study genetic diversity among the circulating
strains.
Materials and methods
Study site
The present study was conducted at the Department of Micro-
biology, Lala Ram Sarup (LRS) Institute of TB and Respiratory
Diseases, New Delhi, India. The Institute is a tertiary care hos-
pital, National Reference Laboratory for the Revised National
Tuberculosis Control Program (RNTCP), and also a DOTS-Plus
site for the treatment of MDR-TB patients. The Laboratory is
efficiently going through the regular rounds of proficiencytesting for both first- and second-line drug sensitivity by the
WHO Supranational TB Reference Laboratory, Institute of
Tropical Medicine; Antwerp, Belgium. Almost all of the cases
for which DSTwas performed were retreatment cases (either
relapse or failure cases). The MDR rate among such patients is
high and falls between 55% – 60% and XDR rates fall between
15% – 20% [12].
Drug susceptibility testing
During the period July 2010 to June 2011 a total of 311M. tuber-
culosis isolates from pulmonary specimens (sputum) were
subjected to first- and second-line DST as requested by the
clinicians. Drug susceptibility testing was performed by
MGIT960 liquid culture system (Becton Dickinson, Franklin
Lakes, NJ, USA) in a BSL III lab at the following critical concen-
trations: rifampicin 1.0 lg/ml, isoniazid 0.1 lg/ml, streptomy-
cin 1.0 lg/ml, ethambutol 5.0 lg/ml, capreomycin 2.5 lg/ml,
ofloxacin 2.0 lg/ml, amikacin 1.0 lg/ml, and kanamycin
2.5 lg/ml.
Spoligotyping and database comparison
Spoligotyping was performed with a commercially available
kit as described earlier [13]. Spoligotypes in binary format
were entered in the SITVIT2 database (Pasteur Institute of
Guadeloupe), which is an updated version of the SpolDB4
[14] and SITVITWEB [15] databases. At the time of the pres-
ent study, SITVIT2 contained more than 3000 SITs with glo-
bal genotyping information on about 87,000 M. tuberculosis
clinical isolates from 160 countries of origin. In this data-
base, SIT (Spoligotype International Type) designates spoli-
gotypes shared by two or more patient isolates, as
opposed to ‘‘orphan’’ which designates patterns reported
for a single isolate. A cluster was defined as two or more
strains with an identical genetic pattern. Major phyloge-
netic clades were assigned according to signatures initially
provided in SpolDB4, and slightly revised in SITVITWEB by
the addition of five ‘‘new rules’’ for definition of variants
within 62 existing lineages/sub-lineages. These include spe-
cific signatures for various M. tuberculosis complex species,
such as Mycobacterium bovis, Mycobacterium microti, Mycobac-
terium caprae, Mycobacterium pinipedii, and Mycobacterium afri-
canum, as well as rules defining major lineages/sub-lineages
for M. tuberculosis sensu stricto. These include the Beijing
clade, the Central Asian (CAS) clade and two sub-lineages,
the East African–Indian (EAI) clade and nine sub-lineages,
the Haarlem (H) clade and three sub-lineages, the Latin
American–Mediterranean (LAM) clade and 12 sub-lineages,
the ‘‘Manu’’ family and three sub-lineages, the S clade,
the IS6110-low-banding X clade and four sub-lineages, and
an ill-defined T clade with five sub-lineages.
Results and discussion
A total of 232/311 isolates were resistant to at least isoniazid
and rifampicin (MDR) and 119 were resistant to four first-line
drugs tested. Among the 232 MDR isolates, 50 (21.5%) met the
definition of XDR-TB. Nonetheless, since the hospital is a
Table 1 – Description of spoligotype patterns observed among XDR M. tuberculosis clinical isolates (n = 50) in Delhi, corresponding Spoligotype International Type (SIT)
numbers, genotypic lineages, and their worldwide distribution in the SITVIT2 database.
SIT (lineage) octal number spoligotype descriptiona Total (%) in study/vs.
database
Distribution in regions with P3% of a given SITb Distribution in countries with P3% of a given
SITsc
21 (42%)/0.22 ASIA-E 34.13, AMER-N 20.95, ASIA-SE 9.46, AFRI-S 8.61,
ASIA-N 7.2, ASIA-S 4.88, EURO-N 3.22
USA 20.6, CHN 19.72, JPN 11.97, ZAF 8.61, RUS 7.2,
VNM 4.05
10 (20%)/0.78 ASIA-S 53.04, AMER-N 17.06, ASIA-W 6.54, EURO-W 6.0,
AFRI-E 5.53, EURO-N 4.52, EURO-S 3.89
IND 30.3, USA 17.06, PAK 11.22, SAU 6.08, BGD 5.84,
IRN 4.83, ITA 3.74, NLD 3.35, ETH 3.35
8 (16%)/0.14 AMER-N 18.2, AMER-S 13.18, EURO-W 11.3, EURO-S
10.49, ASIA-W 7.59, EURO-N 5.94, AFRI-S 5.54, AFRI-E
5.02, ASIA-E 4.72, AFRI-N 3.92
USA 14.71, ITA 5.94, BRA 5.71, ZAF 5.41, TUR 3.87,
AUT 3.82, CHN 3.44, MEX 3.18
1 (2%) / 0.18 ASIA-S 45.26, AMER-N 21.29, EURO-N 11.81, EURO-W
8.23, ASIA-SE 4.83
IND 36.49, USA 21.29, GBR 8.05, NLD 5.72, BGD 4.11,
MYS 3.04, DNK 3.04
1 (2%)/0.19 AFRI-E 29.09, ASIA-W 18.69, AFRI-N 16.18, ASIA-S 12.14,
AMER-N 10.02, EURO-N 5.40, EURO-W 4.43
ETH 27.75, SAU 18.11, SDN 13.30, USA 10.02, IND
6.74, IRN 3.28
1 (2%)/3.45 AFRI-E 41.38, ASIA-W 34.48, ASIA-S 10.34, AMER-N 6.90,
EURO-W 3.45, AFRI-N 3.45
ETH 37.93, SAU 34.48, USA 6.90, IND 6.90, TZA 3.45,
SDN 3.45, PAK 3.45, FXX 3.45
1 (2%)/5.88 ASIA-S 52.94, AMER-N 23.53, EURO-W 5.88, EURO-S 5.88,
EURO-N 5.88, AFRI-N 5.88
IND 52.94, USA 23.53, TUN 5.88, ITA 5.88, GBR 5.88,
DEU 5.88
1 (2%)/5.0 AFRI-E 30.0, AMER-S 25.0, AMER-N 15.0, EURO-S 10.0,
ASIA-S 10.0, EURO-W 5.0, AFRI-S 5.0
ZWE 20.0, USA 15.0, PRY 10.0, MWI 10.0, IND 10.0,
ESP 10.0, ZAF 5.0, NLD 5.0, GUF 5.0, COL 5.0, BRA 5.0
1 (2%)/12.5 ASIA-S 37.5, AMER-N 37.5, EURO-W 12.5, EURO-N 12.5 USA 37.5, IND 25.0, SWE 12.5, NLD 12.5, BGD 12.5
1 (2%)/16.67 EURO-S 33.33, ASIA-W 16.67, ASIA-S 16.67, ASIA-E 16.67,
AMER-S 16.67
ITA 33.33, TWN 16.67, SAU 16.67, IND 16.67, ARG
16.67
1 (2%)/8.33 ASIA-S 50.0, AMER-N 25.0, EURO-W 8.33, CARI 8.33,
AFRI-N 8.33
IND 50.0, USA 25.0, TUN 8.33, DEU 8.33
1 (2%)/20.0 ASIA-S 60.0, EURO-S 40.0 IND 40.0, PRT 20.0, ITA 20.0, BGD 20.0
1 (2%)/100.0 ASIA-S 100.0 IND 100.0
1 (2%)/100.0 ASIA-S 100.0 IND 100.0
a SIT and lineage designations are shown following SITVIT2 proprietary database of Institut Pasteur de la Guadeloupe. Unk, unknown lineages since the pattern did not correspond to a well-defined
signature in the database; note that SIT1345 has a signature close to CAS and was reported as CAS in SpolDB4, but does not follow the rules in a stringent way; hence designated ‘‘unknown’’ in
SITVITWEB. Orphan patterns corresponded to following strains: orphan 1, IND12201041090; orphan 2, IND1220104951 (note that lineage interpretations for orphan patterns are based on expert-based
visual interpretation of the patterns).
b Worldwide distribution is reported for regions with more than 3% of a given SITs as compared to their total number in the SITVIT2 database. The definition of macro-geographical regions and sub-
regions (http://unstats.un.org/unsd/methods/m49/m49regin.htm) is according to the United Nations; Regions: AFRI (Africa), AMER (Americas), ASIA (Asia), EURO (Europe), and OCE (Oceania), sub-
divided in: E (Eastern), M (Middle), C (Central), N (Northern), S (Southern), SE (South-Eastern), and W (Western). Furthermore, CARIB (Caribbean) belongs to Americas, while Oceania is subdivided in
four sub-regions, AUST (Australasia), MEL (Melanesia), MIC (Micronesia), and POLY (Polynesia). Note that in our classification scheme, Russia has been attributed a new sub-region by itself (Northern
Asia) instead of including it among the rest of the Eastern Europe. It reflects its geographical localization as well as due to the similarity of specific TB genotypes circulating in Russia (a majority of
Beijing genotypes) with those prevalent in Central, Eastern and South-Eastern Asia.
c The three letter country codes are according to http://en.wikipedia.org/wiki/ISO_3166-1_alpha-3; countrywide distribution is only shown for SITs withP5% of a given SITs as compared to their total
number in the SITVIT2 database.
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ously treated patients (chronic TB cases), sampling bias can-
not be ruled out, and this data may overestimate the
percentage of both MDR- and XDR-TB. The majority of the pa-
tients (n = 46/50) were in the age group of 15–45. The descrip-
tion of spoligotype patterns observed among XDR M.
tuberculosis clinical isolates, corresponding Spoligotype Inter-
national Type (SIT) designations, genotypic lineages, and their
worldwide distribution in the SITVIT2 database is summa-
rized in Table 1. Spoligotyping revealed 14 patterns; 39/50
(78%) isolates were grouped in three clusters vs. 11/50 (22%)
isolates that were unique. Comparing results with the inter-
national spoligotype database categorized 48 isolates in 12
shared types and two isolates as orphans; 78% of the strains
clustered were divided into three spoligotype international
types: SIT1/Beijing represented the largest cluster (n = 21 iso-
lates; 42%), followed by SIT26/CAS1-Delhi (n = 10 isolates;
20%) and SIT 53/T1 (n = 8 isolates; 16%). One isolate each be-
longed to SIT11, SIT25, SIT247, SIT427, SIT753, SIT1345,
SIT1926, SIT1970 and SIT2148.
With 78% of the isolates grouped in three big clusters, the
overall strain diversity among XDRM. tuberculosis isolates was
lower than in previous reports that included either MDR or
pan-susceptible isolates [9–11,16,17]. This study found SIT1/
Beijing and SIT26/CAS1-Delhi to be predominant among the
XDR isolates in and around the Delhi region, accounting for
nearly 65% of the total isolates spoligotyped. Regarding these
two most predominant types in this study, previous studies
from Delhi have reported their frequent isolation with varying
percentages [9,10]. According to a study conducted at the Hin-
duja Hospital, Mumbai, 62% of all XDR M. tuberculosis isolates
were found to be Beijing upon spoligotyping [18]. The high
prevalence of Beijing and CAS1-Delhi genotypes in the pres-
ent study and as well as in two recent studies on molecular
characterization of M. tuberculosis isolates from patients with
extrapulmonary tuberculosis in North India [19], and Mumbai
[20], underlines the rapid dissemination of these lineages
across large geographical regions. As reviewed previously
[21], the Beijing clade has been associated with young age
(Vietnam) and with drug resistance (Cuba, Germany, Russia,
Estonia and Columbia), whereas no statistically significant
differences were reported in numerous other countries [11].
Hence, larger prospective studies without selection bias are
needed in various geographical regions of India to draw a con-
clusion on the high incidence of the Beijing genotype ob-
served both among MDR and XDR M. tuberculosis isolates in
tertiary care centers in Mumbai [22], as well as in New Delhi
[this study].
Regarding the second largest family among the XDR M.
tuberculosis isolates in this study-the SIT26/CAS1-Delhi geno-
type that belongs to the Central Asian lineage (CAS, n = 11 iso-
lates; 22%)-it has been reported mostly from countries of the
Middle-East and Central Asia, or regions that have witnessed
an important migration to or from the Indian sub-continent,
e.g. Africa, Far-East Asia, Oceania, the United States and Eur-
ope [14,15]. This family has been also identified as a predom-
inant strain in Mumbai [22] and in different regions of the
country [9,10,23,24].
In conclusion, the association of XDR-TB with these preva-
lent clades in this study is cause for major concern withimplications on TB control in India. Community-based stud-
ies with larger recruitment of isolates are now required in or-
der to understand definite transmission patterns and to
identify high-risk groups and areas concerned. Careful char-
acterization of the clades with regard to their virulence and
transmissibility and rapid diagnosis of drug resistance will
be important steps in curtailing chains of transmission and
strengthening the TB control program in India.
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